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Available online xxxxBesides the opioids the standard management of theWorld Health Organization suggests NSAIDs (non-steroidal
anti-inﬂammatory drugs) alone or in combination to enhance analgesia in malignant and non-malignant pain
therapy. The applicability of NSAIDs in a nasal formulation is a new approach in pharmaceutical technology.
In order to enhance the nasal absorption of meloxicam (MX) as an NSAID, its salt form, meloxicam potassium
monohydrate (MXP), registered by Egis Plc., was investigated in comparison with MX. The physico-chemical
properties of the drugs (structural analysis, solubility and dissolution rate) and the mucoadhesivity of nasal for-
mulations were controlled. In vitro and in vivo studies were carried out to determine the nasal applicability of
MXP as a drug candidate in pain therapy.
It can be concluded that MX and MXP demonstrated the same equilibrium solubility at the pH 5.60 of the nasal
mucosa (0.017 mg/ml); nonetheless, MXP indicated faster dissolution and a higher permeability through the
synthetic membrane. The animal studies justiﬁed the short Tmax value (15 min) and the high AUC of MXP,
which is important in acute pain therapy. It can be assumed that the low mucoadhesivity of MXP spray did not
increase the residence time in the nasal cavity, and the elimination from the nasal mucosa was therefore faster
than in the case of MX. Further experiments are necessary to prove the therapeutic relevance of this MXP-con-
taining innovative intranasal formulation.







In vivo test1. Introduction
Intranasal and pulmonary administration are an effective way to
deliver drugs into the systemic circulation as an alternative to the
oral and parenteral routes for some therapeutic agents (Pacławski
et al., 2015). Nasal dosage forms of drugs (spray, gel or powder)
have gained importance in recent years because of the rapid onset
of action, the circumvention of the ﬁrst-pass elimination by the
liver and the gastrointestinal (GI) tract, the non-invasiveness and
the simple daily administration. Nasal transmucosal absorption is af-
fected by the physicochemical properties of the drugs (such as
charge, molecular weight, solubility, pKa, logP and permeability,
etc.) and formulation factors like dosage form, excipients, pH, viscos-
ity, volume or osmolality (Arora et al., 2002; Illum, 2002).tical Technology, University of
Révész).
ffect of solubility enhancemen
16/j.ejps.2016.05.031Intranasal formulations arewell known in pain therapy, in particular
in the case of chronic malignant pain (Striebel et al., 1993). The opioids
(e.g.morphine, butorphanol, fentanyl, etc.) have been formulated as in-
tranasal sprays, reaching Tmax within 25 min, and in the bloodstream
their bioavailability is high (in general, ˃50%) as compared with opioids
administered intravenously with 100% bioavailability (Veldhorst-
Janssen et al., 2009).
TheWorld Health Organization (WHO) has developed a protocol to
guide the treatment of different forms of malignant and non-malignant
pain therapy (WHO, 2007). Fig. 1 summarizes the ladders for painman-
agement. In this standardmanagement, besides the opioids, non-steroi-
dal anti-inﬂammatory drugs (NSAIDs) are suggested for acute pain
therapy or co-administered to enhance analgesia.
NSAIDs, which belong in BCS Class 2 with poor solubility and high
permeability (Tsume et al., 2012), are really important drugs in pain
therapy. Their solubility is pH-dependent (low solubility in acidicmedi-
um) and their permeability is inﬂuenced by various sections of the GI
tract. An increase of the solubility of the NSAID can therefore result in
faster absorption, e.g. from the gastric region, to reach an analgesict on nasal absorption of meloxicam, European Journal of Pharmaceu-
Fig. 1.Management for malignant and non-malignant pain therapy (WHO, 2007).
Fig. 2. Chemical structures of MX (A) and MXP (B).
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lets, capsules and suppositories) are on the market.
The intranasal application of NSAIDs may be an alternative route for
acute pain therapy, with quick transcellular transport, a high plasma
concentration and co-administration with other pain killer to enhance
analgesia. Nonetheless, NSAID-containing nasal products as pain killers
are not available in therapy. One reason may be a low pH value of the
nasal liquid (pH: 5.60) and consequently a low solubility of the NSAID
in this medium, as well as the dose amount, irritation, efﬂux mecha-
nism, etc. The applicability of a NSAID in a nasal formulation is therefore
a new approach in pharmaceutical technology. A dissolvedMX-contain-
ing nasal formulationwas patented by Castile et al. (2005). The aqueous
compositions used co-solvents and contained the dissolved MX in high
concentration,whichwaswell toleratedwhen administered intranasal-
ly and provided rapid and effective systemic drug absorption in an ani-
mal study. Unfortunately, the composition was found to be unstable in
long-term stability tests (precipitation was observed). Another analge-
sic NSAID agent (a ketorolac tromethamine-containing solution) was
successfully administered intranasally to elicit a systemic effect (Li et
al., 2015).
In our previouswork,MXwas chosen asNSAID for intranasal admin-
istration in order to attain an analgesic effect. MX has poor aqueous sol-
ubility (4.4 μg/ml at 25 °C) (Ambrus et al., 2009), andwe therefore used
a “top-down”methodwith the aim of reducing the particle size into the
micro or the nano-range and hence improving its bioavailability, such as
dry ball-milling (Kürti et al., 2011), high-pressure homogenization
(Pomázi et al., 2013) and combined wet milling technology (Bartos et
al., 2015). Nanosuspensions, as potential drug formulations, can be
achieved by combinedwetmilling technology (Liua et al., 2011). The re-
sults indicated that the reduction of the MX particle size into the nano-
range led to increased saturation solubility and dissolution rate, and an
increased adhesiveness to surfaces as compared with micronized MX
particles. In our earlier studies, MX proved not to be toxic in a cell cul-
ture model of the nasal epithelium and did not inﬂuence the
paracellular pathway (Kürti et al., 2013).
In order to enhance thebioavailability ofMX, salt formationmaybe a
new approach to increase its solubility and dissolution rate and to attain
fast absorption through the nasal membrane to reach the blood stream.
One-salt form of MX is meloxicam potassium monohydrate (MXP),
which is a new agent registered by Egis Plc. (Budapest, Hungary) - pat-
ent number: US8097616 B2 (Mezei et al., 2012).
The novel meloxicam potassium salt monohydrate is a valuable in-
termediate in the synthesis of high-purity MX drug substance. The key
intermediate of this protocol is the new potassium salt monohydrate
of meloxicam,whichmakes possible the efﬁcient removal of impurities,
resulting in an environmentally friendly manufacturing process of the
high-purity (N99.90%) drug substance (Mezei et al., 2009).
MXP-containing dosage forms have not been described to date. Our
aimwas therefore to investigate the physicochemical properties ofMXP
in comparison with those of MX and to prepare intranasal liquidPlease cite this article as: Horváth, T., et al., Effect of solubility enhanceme
tical Sciences (2016), http://dx.doi.org/10.1016/j.ejps.2016.05.031formulations with both agents. In vitro and in vivo studies were carried
out to determine the nasal applicability of MXP as a drug candidate in
pain therapy.
2. Materials and methods
2.1. Materials
MX (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-benzothiazine-
3-carboxamide-1,1-dioxide) and MXP (4-hydroxy-2-methyl-N-(5-methyl-
2-thiazolyl)-2H-benzothiazine-3-carboxamide-1,1-dioxide potassium
monohydrate) were obtained from Egis Plc. (Budapest, Hungary) (Fig. 2).
Both of the raw materials are yellow. The melting point of MX is 267 °C
and that of MXP is 253 °C (Hughey et al., 2011). Sodium hyaluronate (HA)
(Mw =1400 kDa) as viscosity enhancer and mucoadhesive agent was ob-
tained as a gift fromGedeon Richter Plc. (Budapest, Hungary). For the rheo-
logical measurements, mucin (porcine gastric mucin type II) and reagents
were purchased from Sigma Aldrich (Sigma Aldrich Co. LLC, St. Louis, MO,
USA).
2.2. Investigation of raw materials
Measurement ofmicrometric properties (SEM, particle size analysis)
and equilibriumsolubilitywere carried out to compareMXandMXPbe-
fore the preparation of the nasal formulations.
2.2.1. Scanning electronmicroscopy (SEM)
SEM (Hitachi S4700, Hitachi Scientiﬁc Ltd., Tokyo, Japan) was used
to visualize the shape and surface characteristics of the samples. The
samples were sputter-coated with gold–palladium under an argon at-
mosphere, using a gold sputter module in a high-vacuum evaporator,
and the samples were examined at 10 kV and 10 μA; the air pressure
was 1.3–13 MPa.
2.2.2. Particle size analysis
The particles of MX and MXP were measured with the Leica Image
Processing and Analysis System (Leica Q500MC, LEICA Cambridge Ltd.,
Cambridge, UK). The particles were described in terms of their length,
breadth, perimeter, roundness and surface area. The roundnesswas cal-
culated from the ratio of the perimeter squared to the area (1). An ad-
justment factor of 1.064 corrected the perimeter for the effect of the
corners produced by the digitization of the image. The mean values
were determined by the examination of 500 particles from each sample.
Roundness ¼ Perimeter
2
4  π  Area  1:064 ð1Þ
2.2.3. Equilibrium solubility of raw materials
The equilibrium solubilities of MX and MXP were determined by a
standardized saturation shake-ﬂask (SSF) method. The speciﬁcations
of the method were published earlier (Baka et al., 2008).
First, 3–15ml of different media (phosphate buffers (PBs) with a pH
of 5.60 or 7.40 andwater with a pH of 5.50) and 5–80mg of MX orMXP
were measured in a glass container to ensure an excess of the solid ma-
terial. After waiting for 1 h, the pH values of the samples were adjusted
with 1 M NaOH or 1 M HCl, depending whether there was a slight shiftnt on nasal absorption of meloxicam, European Journal of Pharmaceu-
3T. Horváth et al. / European Journal of Pharmaceutical Sciences xxx (2016) xxx–xxxin the acid (for MX) or in the alkali (MXP) direction, so as to restore the
original pH of the media. The heterogeneous samples with two phases
were placed into the thermostat at 37 °C for 6 (MX) or 12 h (MXP)
under intensive stirring to ensure solubility equilibrium. The mixers
were then turned off so that the sedimentation of the samples was con-
stant during 18 h (MX) or 36 h (MXP) at 37 °C. Three parallel aliquots
(10–250 μl) were taken out with a Hamilton syringe and diluted (2–
1000 fold) with the current medium if necessary. The concentrations
of the samples were determined by UV spectrophotometry (Jasco V-
550 UV/VIS) at 364 nm. All solubility measurements were carried out
in two parallels, and the value of the solubility was calculated from six
measurement points.
2.2.4. Dissolution test
The paddle method (USP dissolution apparatus, type II Pharma Test,
Hainburg, Germany)was used to examine the rates of dissolution ofMX
andMXP. Themediumwas 100ml PBs of pH 5.60 and 7.40 at 37 °C. The
paddle was rotated at 50 rpm and the sampling was performed up to
60 min. After ﬁltration, the drug contents of the aliquots were deter-
mined by spectrophotometry (Unicam UV/VIS Spectrophotometer,
Cambridge, UK) at 364 nm.
2.3. Preparation and examination of intranasal formulations
2.3.1. Preparation of intranasal sprays
Intranasal formulations, sprays as dosage forms (MX spray or MXP
spray) were developed with 2 mg/ml MX or MXP and 1 mg/ml HA,
where the dispersionmediawas 100ml PBs of pH5.60 at 37 °C. HA-con-
taining liquids with concentrations of 1mg/mlwere prepared, allowing
24 h for swelling in the media and these viscous liquids served as vehi-
cles for the distribution ofMX andMXP. Intranasal formulations contain
the drug in suspended form with a suggested particle size from 5 to
40 μm (Billotte et al., 1999). One PB (pH = 7.40) was made from NaCl
(8.0 g/l), KCl (0.20 g/l), Na2HPO4∗1H2O (1.44 g/l) and KH2PO4 (0.12 g/
l), diluted up to 1000 ml with distilled water. The other PB (pH = 5.6)
was a mixture of stock solutions A and B. 100 ml PB (pH = 5.6) was
made from 94.4 ml stock solution A (containing 9.08 mg/l KH2PO4)
and 5.6 ml stock solution B (containing 11.61 mg/l K2HPO4
concentration).
2.3.2. Examination of intranasal sprays
2.3.2.1. In vitro permeability study. In vitro permeability studies were
carried out on a modiﬁed horizontal Side-Bi-Side™ cell model
(Grown Glass, New York). The two chambers were divided by an
impregnated (with isopropyl myristate) synthetic membrane
(PALL Metricel membrane with 0.45 μm pores). The volumes of
the donor and the acceptor phase were the same (3.0 ml) with a
0.69 cm2 diffusion area. 3.0 ml of nasal spray was used as donor
phase and PB (pH 7.40) served as an acceptor phase. The tempera-
ture of the phases was 37 °C (Thermo Haake C10-P5, Sigma, Aldrich
Co.) and the rotation rate of the stir-bars was set to 100 rpm. Ali-
quots (2.0 ml) were taken from the acceptor phase by pipette and
were replaced with fresh receiving medium at 5, 10, 15 and
60 min of the measurement. The amount of MX or MXP diffused
was determined spectrophotometrically (Unicam UV/VIS) at
364 nm; each sample was measured three times.
The ﬂux (J) of the drug was calculated from the quantity of MX
which has permeated through the membrane after 60 min, divided by
the surface of the membrane insert and the duration [μg/cm2/h]. The
permeability coefﬁcient (Kp) was determined 2) from J and the initial
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taken at 37 °C with a Physica MCR101 rheometer (Anton Paar GmbH,
Graz, Austria). A concentric cylindrical measuring device with a diame-
ter of 10.835 mm was used for the experiment. Viscosity curves were
plotted to determine the viscosity of the samples. In the shear rate inter-
val from 0.1 to 100 1/s, viscosity values were plotted. The method was
based on earlier studies by Bartos et al. (2015). To clarify the roles of
MX and MXP in mucoadhesion, samples were prepared with and with-
outmucin; the samples containingmucinwere stirred for 3 h before the
measurements (the ﬁnal mucin concentration was 5% w/w). The
mucoadhesivity was determined on the basis of the rheological syner-
gism between the polymer and the mucin. The synergism parameter
(bioadhesive viscosity component, ηb) can be calculated from the fol-
lowing Eq. (3):
ηb ¼ ηt–ηm–ηp; ð3Þ
where ηt is the viscosity of the mucin and polymer-containing samples,
and ηm and ηp are the viscosities of the mucin and nasal spray, respec-
tively (Hassan and Gallo, 1990). Three parallel measurements were
used to determine the viscosity values (ηt, ηm and ηp) and the standard
deviations.
2.3.2.3. In vivo study. Each intranasal formulation contained 2mg/mlMX
or MXP and 1 mg/ml HA in phosphate buffer at pH 5.6. A dose of 60 μg
API per animal was administered into the nostrils of male Sprague–
Dawley rats (b.w. 160–180 g, n = 5) via a micropipette. The animals
were anaesthetized with isoﬂurane before the drug administration.
The viscous liquid was slowly ejected into the left nostril and some sec-
onds later into the right nostril (at approximately 45 degree angle).
Blood samples were taken from the tail vein before and 5, 15, 30 and
60 min after the drug administration. The experiments performed
conformed to the European Communities “Council directive for the
care and use of laboratory animals” and were approved by the Hungar-
ian Ethical Committee for Animal Research (registration number: IV/
198/2013). The calculated area under the time–concentration curve
(AUC) was analysed by means of PK Solver 2.0 software (Zhang et al.,
2010) through non-compartmental analysis of plasma data, using the
extravascular input model. The AUCs of the time (min) – concentration
(mg/ml) curves of each animal were ﬁtted with a linear trapezoidal
method.
2.3.2.4. Determination of MX and MXP from the blood samples. The drug
contents of blood samples were quantitated with an Agilent 1260
HLPC system (QP, DAD, ALS). The method was published earlier
(Bartos et al., 2015). MX, MXP and piroxicam (PIR) as internal standard
were separated on a C18 column (Phenomenex Inc., Torrance, CA, USA).
Isocratic elution was performed with 45:55 (v/v) acetonitrile–potassi-
um phosphate buffer solution (0.05 M) (pH adjusted to 2.7 with ortho-
phosphoric acid) at a ﬂow rate of 1.1 ml/min. All the samples were
ﬁltered through a 0.20 μm PES syringe membrane ﬁlter (Phenomenex
Inc., Torrance, CA, USA). The sample injection volume was 10 μl. The
total run timewas 12min, and the column temperature was 30 °C. Con-
centration was measured through the UV absorbance at 254 ± 4 nm.
Qualitative determination was carried out by comparison of the spectra
of standards. Primary stock 0.1 mg/ml solutions of MX, MXP and PIR
were prepared in methanol and stored at −8 °C. Calibration plots of
MX, MXP and PIR were freshly prepared and were linear (R2 N 0.9996
and 0.999, respectively) in the concentration range 0.25–10.0 mg/ml
(n = 3). During the separation, the active substances were eluted
with distinct retention times: 10.12 ± 0.01 (MX and MXP) and
7.36 ± 0.03 min (PIR). The limits of quantiﬁcation (LOQ) were calculat-
ed by working standards with values of 0.171 (MX and MXP) and
0.275 μg/ml (PIR).
The animal blood samples (200 μl) were diluted with 500 μl of ex-
traction liquid (potassium phosphate buffer, 0.03M, pH 2.7) and spikedt on nasal absorption of meloxicam, European Journal of Pharmaceu-
Fig. 3. SEM images of MX (A) and MXP (B).
Table 1
Particle size and roundness of the raw materials.
Sample Length (μm) Breadth (μm) Perimeter (μm) Roundness Area (μm2)
MX 6.451 ± 4.741 3.970 ± 2.577 21.481 ± 18.045 2.081 ± 0.774 22.037 ± 36.102
MXP 12.372 ± 5.894 6.370 ± 2.743 38.300 ± 19.314 2.353 ± 1.007 52.495 ± 46.096
Table 2























5.80 0.040 ± 0.040 8.15 13.10 ± 0.015
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ma concentration of 1.3 mg/ml. The solid phase extraction (SPE) car-
tridges used (Strata-X-C 33 mm Polymeric Strong Cation tubes,
Phenomenex Inc., Torrance, CA, USA) were conditioned with 0.5 ml of
methanol, followed by 0.5 ml of extraction liquid. The prepared blood
samples were allowed to run through the SPE cartridge at a ﬂow rate
of 0.8 ml/min. The cartridges were rinsed with 0.5 ml of extraction liq-
uid and 0.5 ml of methanol (5%) and dried in vacuum for 5 min. Elution
was then performed with 0.5 ml of 5:95 (v/v) ammonium hydroxide–
methanol elution solution and dried in a vacuum oven (Binder, Germa-
ny) at 20–30 mbar and 45 °C for 2–3 h. The dried residue was
reconstituted in 3 ml of eluent and then mixed (60 s), sonicated
(2 min) and centrifuged at 12,000g for 5 min. 20 ml of supernatant
was injected onto the C18 column.
2.3.2.5. Statistical analyses. Data were expressed as means ± SD, and
groups were compared by using Student's t-test. Differences were con-
sidered statistically signiﬁcant when p b 0.05.
3. Results
3.1. Investigation of raw materials
3.1.1. SEM
The SEM images clearly showed the difference between the two
samples (Fig. 3).MX haswell-developed crystals with a smooth surface.
In contrast, the crystals of MXP aremisaligned, and therefore have a dif-
ferent habit (form, surface and size).
3.1.2. Particle size analysis
The results of particle size analysis did not reveal much difference
between MX and MXP (Table 1), which had been anticipated by the
SEM investigations. The crystals of MXP were twice as large as those
of than MX, but the larger surface (area) of MXP could be explained
by the presence of small crystals. The roundness value of the drugs
was the same, but the different habit of the MXP crystals was not
established by Leica investigations.
3.1.3. Equilibrium solubility
The solubilities of the active ingredients inﬂuence the absorption,
and thereforemediawith different pH valueswere used in the solubilityPlease cite this article as: Horváth, T., et al., Effect of solubility enhanceme
tical Sciences (2016), http://dx.doi.org/10.1016/j.ejps.2016.05.031testing. PB at pH 5.60 simulated the pH of the nasal mucosa, while the
PB with pH 7.40 and distilled water as vehicles imitated optional pH
values for the preparation of nasal spray, and the pH of the acceptor
phase was 7.40 in the diffusion tests.
MX is a representative NSAID “oxicam”. It has acidic (enol) with a
pKa of 3.43 and basic (thiazole ring) functional groups. The N basicity
of the thiazole ring prevails in acidic medium (pKa b 1). The pH-depen-
dent solubility of MX is connected to the formation of the anionic form
of the drug due to dissociation of the enolic OH group. Due to the polar-
ity of the anionic form, its solubility shows a large difference as com-
pared with the non-ionic neutral form. The results indicate that the
solubilities of the non-dissociated free acid (MX) and the salt form
(MXP) of the drug are the same at the same pH value of the medium
(Table 2). However, a large difference was detected in distilled water.
MXP was alkali-hydrolysed in water, and the pH value of the saturated
aqueous solution was therefore 8.15, which resulted in a 350-times
higher solubility than that of MX at pH 5.80. This is associated with
the difference in the degree of ionization.
3.1.4. Dissolution testing
The rates of dissolution of MX and MXP were investigated in the
media with pH 5.60 (Fig. 4). Although the equilibrium solubilities of
MX and MXP are the same at pH 5.60 (0.017 mg/ml), the difference in
their rates of dissolution is considerable. This is due to the faster disso-
lution of the salt form and the larger surface of MXP than that of MX
(see Table 1), and consequently the MXP crystals reach saturationnt on nasal absorption of meloxicam, European Journal of Pharmaceu-
Fig. 4. Extent of dissolution of MX and MXP at pH 5.60 (n= 3).
5T. Horváth et al. / European Journal of Pharmaceutical Sciences xxx (2016) xxx–xxxsolubility faster than MX. Fig. 4 shows the amount of MXP dissolved
during 1 h (0.013 mg/ml), which is in good agreement with its equilib-
rium solubility at pH 5.60.
3.2. Examination of intranasal sprays
Intranasal sprays were developed with 2 mg/ml MX or MXP and
1 mg/ml HA. The dispersion media was phosphate buffer with
pH 5.60. The results of the solubility of MX and MXP allow the conclu-
sion that both were really in suspended form (dispersed microcrystals)
in the media.
3.2.1. In vitro permeability
The horizontal cell model (Side-Bi-Side™) was used to measure the
cumulative amounts of MX and MXP that diffused through a synthetic
membrane from nasal sprays against time. Application of this model
provided the continuous stirring of the donor phase because of the ho-
mogeneous distribution of the suspended drugs (Horváth et al., 2015).
Fig. 5 shows that MX spray at pH 5.60 permeate at higher rate through
themembrane thanMXP spray, which indicated a faster diffusion and a
higher drug concentration. This could be explained by the difference in
pH on the two sides of the membrane (acceptor phase at pH 7.40),
which generated a driving force in the system.Fig. 5. In vitro permeability of the sprays through a synt
Please cite this article as: Horváth, T., et al., Effect of solubility enhancemen
tical Sciences (2016), http://dx.doi.org/10.1016/j.ejps.2016.05.031The ﬂux (J), which shows the amounts of MX and MXP that perme-
ate through 1 cm2 of themembranewithin 1 h, was signiﬁcantly higher
in the case of the MXP spray (pH = 5.60) as compared with the MX
spray. The permeability coefﬁcient (Kp) calculated from the ﬂux data
for the MXP spray (pH = 5.60) was also signiﬁcantly higher than in
the MX case (Table 3). The data in the table show the growth trend in
the ﬂux and permeability coefﬁcients for MXP, which are connected to
the salt form, but no connection was found between the in vitro perme-
abilities of MX and MXP and the mucoadhesivities of the sprays.
3.2.2. Mucoadhesion
In our earlier study, intranasal formulations with a low concentra-
tion of HA exhibited a viscoelastic character (Bartos et al., 2015),
which was not inﬂuenced by micro- and nanoparticles of MX. As a vis-
cosity enhancer, HA aids the homogeneous distribution of suspended
drug in the nasal formulation and acts as a mucoadhesive agent,
resulting in a longer residence time on the mucosa. For the rheological
investigation of mucoadhesivity, the nasal formulations were mixed
with 5% mucin and the synergism parameter was calculated from the
viscosity at a shear rate of 100 1/s. Simulating the mucosal surface, the
mucoadhesivities of the sprays containing HA were measured in PB at
pH 5.60, without drugs as with MX or MXP.
HAs are mucoadhesive polymers, which was veriﬁed in our experi-
ments (positive synergism value) (Fig. 6). When suspended drughetic membrane containing MX and MXP (n= 3).
t on nasal absorption of meloxicam, European Journal of Pharmaceu-
Table 3
Flux (J) and permeability coefﬁcient (Kp) values of nasal sprays.
J [μg/cm2/h] Kp [cm/h]
MX spray (pH = 5.60) 31.30 0.0157
MXP spray (pH = 5.60) 204.60 0.1023
Fig. 6. Calculated synergism parameters of the samples at a shear rate of 100 1/s (n= 3).
6 T. Horváth et al. / European Journal of Pharmaceutical Sciences xxx (2016) xxx–xxx(MX) was used in the formulation, the synergism was increased (MX
spray). The suspended drug improved and promoted the format of
netpoints between the HA and the mucin polymers, result in marked
mucoadhesivity. Addition of the ionic drug (MXP) decreased the syner-
gism, which can be explained by the interaction of the salt and the HA
polymers (Krüger-Szabó et al., 2015).3.2.3. In vivo permeability
The plasma concentration of the drug in rats is shown in Fig. 7. In the
event of the MXP-containing spray, a 3 times higher plasma level was
observed after 5 min as compared with the formulation containing
MX. This is in accordance with the faster dissolution and faster absorp-
tion of MXP from the medium at pH 5.6. The difference in
mucoadhesivity of the MX and MXP-containing sprays at pH 5.60 (see
Fig. 4) does not signiﬁcantly inﬂuence the drug absorption throughFig. 7. Plasma drug concentration vs. time proﬁles in rats after intrana
Please cite this article as: Horváth, T., et al., Effect of solubility enhanceme
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centration (Tmax) was reached at 15 min, after the elimination had be-
come predominant.
The AUC is proportional to the amount of drug absorbed during the
investigated time interval (Fig. 8). The calculated AUCvalueswere grad-
ually increased by using the salt form (from AUCMX: 10.927 min∗μg/ml
to AUCMXP: 29.738 min∗μg/ml). Our results demonstrated a correlation
between the value of AUC and the non-dissociated free acid (MX) and
salt (MXP) forms of the drug.
4. Discussion
The applicability of NSAIDs in a nasal formulation is a new approach
in pain therapy. MXwas the ﬁrst enolic acid oxicam derivative patented
for intranasal administration (Castile et al., 2005). MX has poor water
solubility and is relatively well-permeable, and different strategies
were therefore used to increase its dissolution rate and solubility
(Ambrus et al., 2009, Kürti et al., 2013).
MX is applied in solid dosage forms, indicating prolonged absorption
(the Cmax value of MX is within 4–5 h), (Busch et al., 1998), which can-
not use for rapid analgesia. According to our pervious results, the phar-
macokinetics of nasally applied MX nanoparticles was similar to that
after intravenous injection: the Cmax was reached within 5 min (Kürti
et al., 2013). Nasal absorption can be improved through the higher
mucoadhesivity of the MX-containing formulation, which increases
the residence time in the nasal cavity, and the formation of a well-struc-
tured system can ensure the controlled release of MX without Cmax
(Bartos et al., 2015).
In order to enhance the bioavailability of MX, salt formation was a
new approach to increase its solubility, dissolution rate and fast absorp-
tion through the nasal membrane to reach the blood stream. The potas-
sium salt MXP was a new agent registered by Egis Plc. (Budapest,
Hungary) (patent number: US8097616 B2). MXP-containing dosage
forms have not been described to date, and therefore we investigated
the physico-chemical properties of MXP in comparison with MX and
prepared intranasal liquid formulations with both agents. In vitro and
in vivo studies were carried out to determine the nasal applicability of
MXP as a drug candidate in pain therapy.
Our results demonstrated that both of the raw materials consist of
yellow crystals, but different habits. MX and MXP have high melting
points (MX = 267 °C and MXP = 253 °C). The solubilities of the non-
dissociated free acid (MX) and salt form (MXP) of the drug are equal
at the same pH of the medium (PB pH= 5.60 or 7.40). The equilibriumsal administration of the sprays containing MX and MXP (n= 5).
nt on nasal absorption of meloxicam, European Journal of Pharmaceu-
Fig. 8. AUCs of the sprays containing MX and MXP (n= 5).
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value (pH = 7.40), but a considerable difference was detected in dis-
tilled water at own pH. MXP was alkali-hydrolyzed in water and the
pH value of saturated aqueous solution was 8.15, which resulted in a
350-times higher solubility than that of MX in water at pH 5.80. This
was associated with the difference in degree of ionization.
Although the solubilities of MX and MXP are the same at pH 5.60
(0.017 mg/ml), the difference in their rates of dissolution is consider-
able. This difference stems from the faster dissolution and larger surface
ofMXP, and consequently theMXP crystals can reach saturation solubil-
ity faster than as MX. The amount of MXP dissolved during 1 h
(0.013 mg/ml) is in good agreement with its equilibrium solubility at
pH 5.60.
The in vitro permeability results on a synthetic membrane suggest
the potential usefulness of theMXP spray (pH=5.60) for nasal delivery
because of the higher permeability value in comparison with the MX
spray (pH = 5.60). Experiments where MXP spray was administered
nasally into rats (as compared with MX spray) showed that the maxi-
mum concentration Tmax was reached at 15 min, and the calculated
AUC values gradually increased in use of the salt form. It was found
that the difference inmucoadhesivity ofMXandMXP-containing sprays
did not signiﬁcantly inﬂuence the drug absorption through the nasal
membrane.
It is known that intranasal administration can allow the drug absorp-
tion not only in the bloodstream but also in the central nervous system
(CNS). The direct pathways as the olfactory nerve and the olfactory ep-
ithelial are known for transfer of drugs into the CNS (Huston and
Schwarting, 1997). Intranasal administration of NSAIDs as MX and
MXP is new approach in the pain therapy, therefore the study of direct
transport can assist the understanding of the rapid analgesia.
5. Conclusion
In conclusion we demonstrated that using salt form can result a
faster dissolution and enhance the bioavailability. Nasal delivery, as an
alternative way, could offer a great solution for drug administration.
Both the in vitro and the in vivo results indicated thatMXP could be sug-
gested for the development of an intranasal liquid dosage form for use
in rapid pain management, but further experiments are necessary to
prove the therapeutic relevance of this MXP-containing innovative in-
tranasal formulation.
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